Cabazitaxel + prednisone
Checked 2026-09-09
Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cabazitaxel Cytotoxic chemotherapy (taxane) | 20 mg/m² (25 mg/m² in selected patients) | IV | D1 | |
Prednisone | 10 mg once daily | Oral | D1-21 |
Cycles
until progression (up to 10)
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Recommended
Notes
- Primary G-CSF prophylaxis is advised at 25 mg/m² and for patients over 65 or with prior febrile neutropenia.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Docetaxel + prednisone
Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer
every 21 days × 6
Abiraterone + prednisone with ADT
High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer
every 28 days
177Lu-PSMA-617
PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane
every 42 days × 6
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2